Author Topic: Addressing the rising prices of DMTs for MS (JAMA Neurol.)  (Read 27 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
Addressing the rising prices of DMTs for MS (JAMA Neurol.)
« on: November 12, 2019, 10:34:34 am »

From JAMA Neurology (August 26, 2019)--"Addressing the rising prices of disease-modifying therapies for multiple sclerosis." The authors are dealing with self-administered disease-modifying MS drugs.

http://bit.ly/34UPyj5


And in the same issue of JAMA Neurology, "Trends in prices, market share, and spending on self-administered disease-modifying therapies for multiple sclerosis in Medicare Part D":


http://bit.ly/2KfvArz
« Last Edit: November 12, 2019, 10:39:05 am by agate »
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8568
  • MS diagnosed 1980
  • Location: Pacific Northwest
The MS Society has objected to the high price of the new drug Vumerity--from Multiple Sclerosis News Today (November 14, 2019), "National MS Society Objects to $88,000 List Price of Vumerity":


http://bit.ly/2KGCypV
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
51 Views
Last post October 21, 2016, 02:53:46 pm
by agate
0 Replies
85 Views
Last post December 29, 2016, 03:03:18 pm
by agate
0 Replies
291 Views
Last post August 18, 2017, 04:44:58 pm
by agate
0 Replies
128 Views
Last post August 26, 2019, 04:45:30 pm
by agate
0 Replies
35 Views
Last post October 11, 2019, 07:19:01 am
by agate